Home
Applications
Indications
Business
EpiSwitch
®
Products
EpiSwitch
®
Checkpoint Inhibitor Response Test
EpiSwitch
®
COVID-19 Severity Test
EpiSwitch
®
Explorer Array Kit
EPISWITCH
®
ANALYTICAL PORTAL
EpiSwitch
®
Service
Investors
Investors Overview
Results and Presentations
Share Price Information
Regulatory News
Board & Governance
Key Corporate Documents
AIM Rule 26
Email Alerts
Investor Contacts
News
About Us
History
Board of Directors
Management Team
Scientific Advisory Panel
Values
Careers
Contact Us
OBD raises in excess of $7 million to accelerate the commercialisation of its epigenetic platform technology - EpiSwitch™.
July 16, 2015
|
In
Milestones
|
By
Aroul Ramadass
Prev
Next
Privacy Preference Center
Privacy Preferences